Regulated information – inside information
Nazareth (
Key Highlights
- Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5% organic revenue growth at CER supported by growth across all regions
- 13.9% REBITDA increase translates to 40bps REBITDA margin uplift YoY to 19.5%, reflecting synergies from
North America acquisitions and operational excellence benefits - Operating cash flow increases by 13.9% to €124.6 million resulting in improved leverage ratio of 1.4x
- Acquisition of
London Specialist Pharmacy in theUnited Kingdom - Dividend proposal of €0.30 per share (+20%)
- Good progress on greenhouse gas intensity reduction target
- FY ’24 outlook of high single-digit organic sales growth and continued improvement in profitability
“I am very pleased to present another set of strong results, exemplifying the resilience of Fagron’s diversified business model. In line with our guidance, we have delivered outstanding organic revenue growth of 10.5% at CER YoY and an improved margin, as we progressed on successfully integrating our acquisitions in
Growth in the EMEA region normalized towards the end of this year as expected, reflecting a solid performance across most of our markets and the impact of the anticipation on the local reimbursement reform in
The acquisition of
For full year 2024, we expect high single-digit organic revenue growth and our profitability to improve YoY. We remain confident in achieving our mid-term objectives and continue to look for attractive growth opportunities that support our strategic ambitions.”
Please open the link below for the full press release:
Attachment
Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023
© OMX, source